Johnson & Johnson (NYSE:JNJ) Institutional Investors Sentiment Index Increased in 2019 Q2

Johnson & Johnson (NYSE:JNJ) Logo

Sentiment for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) institutional sentiment increased to 0.88 in 2019 Q2. Its up 0.04, from 0.84 in 2019Q1. The ratio is more positive, as 754 active investment managers increased or opened new stock positions, while 861 decreased and sold equity positions in Johnson & Johnson. The active investment managers in our partner’s database now own: 1.83 billion shares, down from 1.84 billion shares in 2019Q1. Also, the number of active investment managers holding Johnson & Johnson in their top 10 stock positions decreased from 477 to 439 for a decrease of 38. Sold All: 48 Reduced: 813 Increased: 628 New Position: 126.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $342.61 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 21.68 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

The stock increased 0.10% or $0.12 during the last trading session, reaching $130.55. About 3.05 million shares traded. Johnson & Johnson (NYSE:JNJ) has declined 1.48% since September 13, 2018 and is downtrending. It has underperformed by 1.48% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on October, 15. They expect $2.00 earnings per share, down 2.44 % or $0.05 from last year’s $2.05 per share. JNJ’s profit will be $5.25B for 16.32 P/E if the $2.00 EPS becomes a reality. After $2.58 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -22.48 % negative EPS growth.

Robert Wood Johnson Foundation holds 100% of its portfolio in Johnson & Johnson for 13.00 million shares. Pettee Investors Inc. owns 130,474 shares or 11.54% of their US portfolio. Moreover, Cincinnati Indemnity Co has 11.21% invested in the company for 25,000 shares. The United Kingdom-based Independent Franchise Partners Llp has invested 9.76% in the stock. Armstrong Henry H Associates Inc, a Pennsylvania-based fund reported 434,467 shares.

Since January 1, 0001, it had 1 buy, and 0 insider sales for $419,040 activity.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Ratings analysis reveals 60% of Johnson & Johnson’s analysts are positive. Out of 5 Wall Street analysts rating Johnson & Johnson, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $140 while the high is $157. The stock’s average target of $148.80 is 13.98% above today’s ($130.55) share price. JNJ was included in 13 notes of analysts from March 15, 2019. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, April 17 report. Raymond James maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 17. Raymond James has “Outperform” rating and $147 target. As per Wednesday, July 17, the company rating was maintained by Raymond James. The company was maintained on Tuesday, August 27 by Morgan Stanley. The rating was initiated by Barclays Capital on Friday, June 21 with “Hold”. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, April 17. Credit Suisse maintained Johnson & Johnson (NYSE:JNJ) on Thursday, May 16 with “Outperform” rating. On Monday, March 25 the stock rating was maintained by Raymond James with “Buy”. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, April 17.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Johnson & Johnson’s Definitive Tests (Part 1) – Seeking Alpha” on September 11, 2019, also with their article: “After Hours: Johnson & Johnson Loses Opioid Case, Amazon Allegedly Loses Top Executive – Yahoo Finance” published on August 26, 2019, published: “An Intrinsic Calculation For Johnson & Johnson (NYSE:JNJ) Suggests It’s 43% Undervalued – Yahoo Finance” on September 09, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “What Are Analysts Saying About The Future Of Johnson & Johnson’s (NYSE:JNJ)? – Yahoo Finance” published on July 25, 2019 as well as‘s news article titled: “How Much Will It Cost Johnson & Johnson To Settle Most of Its Lawsuits? – Forbes” with publication date: August 26, 2019.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.